vitamin d receptor

Calcitriol (1,25-Dihydroxyvitamin D3) is a metabolite of vitamin D and a vitamin D receptor (VDR) agonist (IC50=0.4 nM). Calcitriol increases intestinal absorption of calcium and phosphorus, and increases bone resorption with parathyroid hormone.

Ergocalciferol (Vitamin D2 (Calciferol)) is a derivative of ergosterol formed by ultraviolet rays breaking of the C9-C10 bond with a strong inhibitory effect against bladder tumor promotion by sodium saccharin, and it induces cell differentiation in leukemia cells. Vitamin D2 is an inhibitor of DNA Polymerase.

Vitamin D3 (cholecalciferol) is a naturally occurring form of vitamin D; once metabolically activated, it can induce cellular differentiation and cancer cell proliferation. Vitamin D3 can be used to establish kidney stone models and is also an important research target in the fields of immunology and oncology.

Calcipotriol (MC 903) is a synthetic vitamin D3 analogue with high affinity for the vitamin D receptor.

Maxacalcitol (22-Oxacalcitriol) is a ligand of VDR-like receptors and a non-serum calcium vitamin D3 analogue. Maxacalcitol inhibits parathyroid hormone (PTH) mRNA expression in vitro and in vivo.

Seocalcitol is an analog of vitamin D, binds vitamin D receptor protein from human osteosarcoma MG-63 cells(Kd : 0.27 nM).

Inecalcitol is a unique vitamin D3 analog that induces apoptosis and has anticancer activity. It is an orally active vitamin D receptor agonist with a Kd of 0.53 nM.

Doxercalciferol (TSA 840) is a synthetic vitamin D2 analog, suppressing parathyroid synthesis and secretion, used to treat secondary hyperparathyroidism and metabolic bone disease.

Alfacalcidol (Etalpha) (1-hydroxycholecalciferol; Alpha D3; 1.alpha.-Hydroxyvitamin D3) is a non-selective VDR activator medication.

Calcifediol (U 32070E) is a naturally occurring product that is metabolized in the liver from vitamin D3, a VDR ligand. Calcifediol is indicated for use as a vitamin supplement for all patients with vitamin D deficiency.

Calcifediol monohydrate (25-hydroxy Vitamin D3 monohydrate), the primary circulating metabolite of Vitamin D3, serves as a potent VDR inhibitor.

Paricalcitol is a selective vitamin D receptor agonist and a vitamin D analog. Paricalcitol potently inhibits the synthesis and secretion of parathyroid hormone (PTH) and is commonly used in studies of secondary hyperparathyroidism in patients with chronic kidney disease.

Calcipotriol monohydrate is an analog of Vitamin D3 with a high affinity for the vitamin D receptor. Calcipotriol monohydrate can be used for studies about psoriasis.

Calcitriol-D6 is the deuterated form of Calcitriol, which is the hormonally active form of vitamin D. Calcitriol (T6316) is the active metabolite of vitamin D3 that activates the vitamin D receptor.

Doxercalciferol-D3 is the deuterated form of Doxercalciferol (T6112) and ACTS as vitamin D receptor activator (VDRA), which is a vitamin D2 analogue.

Impurity B of Calcitriol is an impurity of Calcitriol. Calcitriol is the hormonally active form of vitamin D, Calcitriol is the active metabolite of vitamin D3 that activates the vitamin D receptor (VDR).

trans-Doxercalciferol, an isomer of Doxercalciferol, is a Vitamin D receptor activator that prevents renal disease.

VDR agonist 1 (compound 28), a nonsteroidal Vitamin D receptor (VDR) agonist, demonstrates potent activity with a low IC 50 of 690 nM in MCF-7 cells. It inhibits cell cycle progression through upregulation of p21 and p27, and induces apoptosis by elevating BAX expression while reducing Bcl-2 levels [1].

Calcitriol Impurities A refers to the contaminants found in Calcitriol, the hormonally active metabolite of vitamin D3, which serves to activate the vitamin D receptor.

VDR agonist 3 (Compound E15) is a potent activator of the vitamin D receptor (VDR). It effectively inhibits the activation of hepatic stellate cells (HSC) via VDR. In a model of liver fibrosis induced by CCl4 in mice, VDR agonist 3 significantly alleviates liver fibrosis without causing hypercalcemia.

UG-650 is a UVB1 non-gemini analogue that incorporates structural features of both UVB1 and MC 1288. It has the ability to bind to the vitamin D receptor (VDR), thereby inhibiting the proliferation of MCF-7 cells and the migration of MC3T3-E1 cells.

20-Hydroxyvitamin D3 (20(OH)D3) is a hydroxy metabolite of vitamin D3. It functions as a ligand for the vitamin D receptor (VDR), aryl hydrocarbon receptor (AhR), liver X receptor (LXR), and retinoic acid receptor-related orphan receptor (ROR). 20-Hydroxyvitamin D3 inhibits cell proliferation and induces differentiation. It is applicable in research on inflammatory and autoimmune diseases.

ZG-126 is an agonist of the vitamin D receptor (VDR) and an inhibitor of histone deacetylase (HDAC) with an IC50 range of 0.63-67.6 μM. It demonstrates cytotoxicity in cancer cell lines MDA-MB-231 and 4T1. In mouse models, ZG-126 exhibits antitumor and antimetastatic effects against melanoma and triple-negative breast cancer (TNBC). Additionally, it shows anti-inflammatory activity by reducing macrophage infiltration and polarization to the immunosuppressive M2 subtype.

19-Nor-22-oxa-1a,25(OH)2-VD3 is a vitamin D₃ analog characterized by its extremely low affinity for the vitamin D receptor (VDR) and minimal binding to the vitamin D binding protein (DBP). It is effective in inducing differentiation in HL-60 cells and causes cell cycle arrest at the G₀-G₁ phase. This compound can be utilized in research pertaining to diseases such as hyperparathyroidism.